Circulating adenosine increases during human experimental endotoxemia but blockade of its receptor does not influence the immune response and subsequent organ injury

Critical Care

Volumn 15, Issue 1, 2011, Pages

  Ramakers, Bart P ^a   Riksen, Niels P ^a   van den Broek, Petra ^a   Franke, Barbara ^a   Peters, Wilbert H M ^a   van der Hoeven, Johannes G ^a   Smits, Paul ^a   Pickkers, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE MONOPHOSPHATE DEAMINASE; ADENOSINE RECEPTOR; CAFFEINE; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; VASCULAR CELL ADHESION MOLECULE 1; ADENOSINE RECEPTOR BLOCKING AGENT; AMPD1 PROTEIN, HUMAN; LIPOPOLYSACCHARIDE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM INJURY; ENDOTOXEMIA; FEMALE; HETEROZYGOTE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IN VIVO STUDY; KIDNEY INJURY; MALE; NONSENSE MUTATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; TISSUE INJURY; URINARY EXCRETION; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESCHERICHIA COLI; GENETICS; INFLAMMATION; INJURY; INNATE IMMUNITY; KIDNEY;

ADENOSINE; AMP DEAMINASE; CAFFEINE; DOUBLE-BLIND METHOD; ENDOTOXEMIA; ESCHERICHIA COLI; HUMANS; IMMUNITY, INNATE; INFLAMMATION; KIDNEY; LIPOPOLYSACCHARIDES; MALE; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1;

EID: 78650907526     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9400     Document Type: Article

References (38)

1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003, 168:165-172. 10.1164/rccm.2201087, 12851245.
2. Martin C, Leone M, Viviand X, Ayem ML, Guieu R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. Crit Care Med 2000, 28:3198-3202. 10.1097/00003246-200009000-00014, 11008982.
3. Jabs CM, Sigurdsson GH, Neglen P. Plasma levels of high-energy compounds compared with severity of illness in critically ill patients in the intensive care unit. Surgery 1998, 124:65-72.
4. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996, 157:4634-4640.
5. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001, 414:916-920. 10.1038/414916a, 11780065.
6. Soop A, Johansson C, Hjemdahl P, Kristiansson M, Gyllenhammar H, Li N, Sollevi A. Adenosine treatment attenuates cytokine interleukin-6 responses to endotoxin challenge in healthy volunteers. Shock 2003, 19:503-507. 10.1097/01.shk.0000051756.08171.11, 12785003.
7. Anderson JL, Habashi J, Carlquist JF, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Hart N. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000, 36:1248-1252. 10.1016/S0735-1097(00)00850-0, 11028479.
8. Riksen NP, Franke B, Oyen WJ, Borm GF, van den BP, Boerman OC, Smits P, Rongen GA. Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. Eur Heart J 2007, 28:1085-1091. 10.1093/eurheartj/ehm032, 17376785.
9. van Eijk LT, Dorresteijn MJ, Smits P, van der Hoeven JG, Netea MG, Pickkers P. Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med 2007, 35:1464-1469. 10.1097/01.CCM.0000266534.14262.E8, 17452928.
10. Dorresteijn MJ, van Eijk LT, Netea MG, Smits P, van der Hoeven JG, Pickkers P. Iso-osmolar prehydration shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia. J Endotoxin Res 2005, 11:287-293.
11. Christ F, Bauer A, Brugger D, Niklas M, Gartside IB, Gamble J. Description and validation of a novel liquid metal-free device for venous congestion plethysmography. J Appl Physiol 2000, 89:1577-1583.
12. Leslie SJ, Attina T, Hultsch E, Bolscher L, Grossman M, Denvir MA, Webb DJ. Comparison of two plethysmography systems in assessment of forearm blood flow. J Appl Physiol 2004, 96:1794-1799. 10.1152/japplphysiol.00567.2002, 14752120.
13. Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, Rongen GA. Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 2006, 48:700-707. 10.1016/j.jacc.2006.04.083, 16904537.
14. Smits P, Schouten J, Thien T. Cardiovascular effects of two xanthines and the relation to adenosine antagonism. Clin Pharmacol Ther 1989, 45:593-599. 10.1038/clpt.1989.79, 2659234.
15. Ramakers BP, Pickkers P, Deussen A, Rongen GA, van den BP, van der Hoeven JG, Smits P, Riksen NP. Measurement of the endogenous adenosine concentration in humans in vivo: methodological considerations. Curr Drug Metab 2008, 9:679-685. 10.2174/138920008786049249, 18855606.
16. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215. 10.1093/nar/16.3.1215, 334765, 3344216.
17. Ronaghi M. Pyrosequencing for SNP genotyping. Methods Mol Biol 2003, 212:189-195.
18. Prabhakar U, Eirikis E, Davis HM. Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay. J Immunol Methods 2002, 260:207-218. 10.1016/S0022-1759(01)00543-9, 11792390.
19. Heemskerk S, Pickkers P, Bouw MP, Draisma A, van der Hoeven JG, Peters WH, Smits P, Russel FG, Masereeuw R. Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am Soc Nephrol 2006, 1:853-862. 10.2215/CJN.00490206, 17699297.
20. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 2010, 34:10-16.
21. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology 1993, 187:403-416.
22. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999, 51:83-133.
23. Rongen GA, Brooks SC, Ando S, Notarius CF, Floras JS. Caffeine abstinence augments the systolic blood pressure response to adenosine in humans. Am J Cardiol 1998, 81:1382-1385. 10.1016/S0002-9149(98)00177-5, 9631984.
24. Ohta A, Lukashev D, Jackson EK, Fredholm BB, Sitkovsky M. 1,3,7-trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol 2007, 179:7431-7438.
25. Horrigan LA, Kelly JP, Connor TJ. Caffeine suppresses TNF-alpha production via activation of the cyclic AMP/protein kinase A pathway. Int Immunopharmacol 2004, 4:1409-1417. 10.1016/j.intimp.2004.06.005, 15313438.
26. Eigler A, Greten TF, Sinha B, Haslberger C, Sullivan GW, Endres S. Endogenous adenosine curtails lipopolysaccharide-stimulated tumour necrosis factor synthesis. Scand J Immunol 1997, 45:132-139. 10.1046/j.1365-3083.1997.d01-377.x, 9042424.
27. Horrigan LA, Kelly JP, Connor TJ. Immunomodulatory effects of caffeine: friend or foe?. Pharmacol Ther 2006, 111:877-892. 10.1016/j.pharmthera.2006.02.002, 16540173.
28. Soop A, Sunden-Cullberg J, Albert J, Hallstrom L, Treutiger CJ, Sollevi A. Adenosine infusion attenuates soluble RAGE in endotoxin-induced inflammation in human volunteers. Acta Physiol (Oxf) 2009, 197:47-53. 10.1111/j.1748-1716.2009.01985.x, 19302259.
29. Martin L, Pingle SC, Hallam DM, Rybak LP, Ramkumar V. Activation of the adenosine A3 receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2006, 316:71-78. 10.1124/jpet.105.091868, 16188954.
30. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000, 275:4429-4434. 10.1074/jbc.275.6.4429, 10660615.
31. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. Eur J Pharmacol 1998, 358:261-268. 10.1016/S0014-2999(98)00619-0, 9822893.
32. Morisaki T, Gross M, Morisaki H, Pongratz D, Zollner N, Holmes EW. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992, 89:6457-6461. 10.1073/pnas.89.14.6457, 49520, 1631143.
33. Kalsi KK, Yuen AH, Rybakowska IM, Johnson PH, Slominska E, Birks EJ, Kaletha K, Yacoub MH, Smolenski RT. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation--a potential mechanism of protection in heart failure. Cardiovasc Res 2003, 59:678-684. 10.1016/S0008-6363(03)00497-8, 14499869.
34. Loh E, Rebbeck TR, Mahoney PD, DeNofrio D, Swain JL, Holmes EW. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation 1999, 99:1422-1425.
35. Bodin P, Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res 1998, 47:351-354. 10.1007/s000110050341, 9754870.
36. Gorlach A. Control of adenosine transport by hypoxia. Circ Res 2005, 97:1-3. 10.1161/01.RES.0000174112.36064.77, 16002753.
37. Thiel M, Caldwell CC, Sitkovsky MV. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microbes Infect 2003, 5:515-526. 10.1016/S1286-4579(03)00068-6, 12758281.
38. German DC, Kredich NM, Bjornsson TD. Oral dipyridamole increases plasma adenosine levels in human beings. Clin Pharmacol Ther 1989, 45:80-84. 10.1038/clpt.1989.12, 2910640.